Decheng entities disclose multi‑million BYSI stakes via Form 3
Rhea-AI Filing Summary
Decheng Capital and related funds disclosed initial beneficial ownership in BeyondSpring Inc. (BYSI). Three Decheng-managed funds report indirect holdings of 1,979,072, 1,903,579 and 1,000,000 ordinary shares respectively. The filings indicate indirect ownership through general partner entities and identify Dr. Xiangmin Cui as manager with disclaimers of ownership except for pecuniary interest. No derivative securities are reported.
Positive
- Three institutional funds managed by Decheng disclose substantial holdings, showing committed institutional investment in BYSI.
- Clear ownership structure is provided: holdings are held by funds and attributed to GP entities with manager identified.
- No derivative securities reported, reducing complexity around potential option dilution or contingent claims.
Negative
- None.
Insights
TL;DR: Institutional Decheng entities disclose substantial indirect stakes in BYSI totaling multi‑million ordinary shares; no derivatives reported.
The Form 3 disclosures list three Decheng-managed funds holding sizeable indirect positions in BeyondSpring, with holdings of 1,979,072; 1,903,579; and 1,000,000 ordinary shares. Ownership is reported indirectly through GP entities with Dr. Xiangmin Cui identified as manager and disclaimers limiting beneficial ownership to pecuniary interest. The absence of reported derivative positions simplifies the ownership picture for investors assessing potential dilution or option-based exposure.
TL;DR: Disclosure signals concentrated institutional ownership and clear GP/manager relationships; governance implications are disclosure‑driven, not operational.
The filing clarifies that the positions are held by limited partnership funds and attributed indirectly to their general partner entities and the manager, Dr. Xiangmin Cui. Each GP and Dr. Cui include standard disclaimers of beneficial ownership except to the extent of pecuniary interest. The Form 3 is a routine ownership disclosure; it documents significant stakes but contains no governance actions, board changes, or agreements affecting control.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Footnotes (1)
- These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. These securities are held directly by Decheng Capital China Life Sciences USD Fund II, L.P. ("Fund II"). Decheng Capital Management II (Cayman), LLC ("GP II") is the general partner of Fund II. Dr. Cui is the manager of GP II. Each of Fund II, GP II and Dr. Cui may be deemed to beneficially own the securities held by Fund II. Each of GP II and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.
